Verilumia 
Kodiak Reports Positive Phase 3 Results for Two Eye Drugs
Kodiak Sciences said its experimental treatments Zenkuda and KSI501 met the primary endpoints in a Phase 3 study of wet age-related macular degeneration, prompting a sharp rise in the company’s shares.
